STEVENSON, Md., Jan. 03, 2018 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of Ohio on behalf of purchasers of Meridian Bioscience, Inc. (NASDAQ:VIVO) (“Meridian” or the “Company”) securities during the period between March 25, 2016 and July 13, 2017, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until January 16, 2018 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Meridian securities during the Class Period. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that Meridian’s lead tests provide inaccurate results.
According to the complaint, following a May 17, 2017 press release by the U.S. Food and Drug Administration (“FDA”) warning about the inaccuracy of the Company’s lead tests, and a July 13, 2017 statement by the FDA regarding the status of the investigation into the inaccurate results, the value of Meridian shares declined significantly.
If you have suffered a loss in excess of $100,000 from investment in Meridian securities purchased on or after March 25, 2016 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/casesandinvestigations.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
[email protected]


FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 



